Leadership Team2018-09-28T10:54:51+00:00

Leadership Team

Board of Directors

Scott Dresden, MD, FACOG
Dr. Dresden is currently a general partner in Dresden Capital. He is a board certified OB/GYN, having delivered over 7,000 babies during his career. He is the holder of 11 patents and was the winner of two Ingram Research Awards early in his career. He is also the founder of several companies.

Dr. Dresden is a graduate of the University of Florida, where he earned a Bachelor of Science in microbiology. In addition, he earned his Medical Degree from the University of South Florida.

James B. Stubbs, Ph.D.
Dr. James B. Stubbs, Ph.D., served as Chief Executive Officer and President at OBMedical Company from September 21, 2015 to March 21, 2016. Dr. Stubbs is a Startup Catalyst at Advanced Technology Development Center. Dr. Stubbs served as the Chief Science Officer at Cianna Medical, Inc. He founded Radiation Dosimetry Systems of Oak Ridge, Inc. (RDS) and served as its President. He served as Chief Technology Officer of Proxima, where he expanded its IP portfolio via patent filings and acquisitions and performed technical due diligence on potential new technologies and competitive products. He also served as a Consultant to Proxima for a year. He was Founder and served as Chief Technology Officer and Director of Focal Therapeutics, Inc. He has co-authored 48 peer-reviewed scientific articles in the brachytherapy and radiopharmaceutical fields.

Dr. Stubbs is a graduate of the University of Virginia, where he earned a Masters of Science and Ph.D. in Nuclear Engineering and Medical Physics. In addition, he earned a Bachelor of Science in Nuclear Engineering from the University of Florida.

Mark A. Samuels

Mr. Samuels is a proven entrepreneur, inventor and seasoned senior executive with a strong background in product development, commercialization and sales of medical devices. With over 20 years of experience in executive management and corporate governance for both public and privately held technology companies, including women’s health, he brings a broad range of experience in government and strategic partner funding, equity investment and IPO. Mark was previously CEO and co-founder of Guided Therapeutics (SpectRx) , where he guided the Company to a $180 million dollar valuation after a successful IPO. After 10 years of experience as a public company CEO, Mr. Samuels worked with various startups including LumaMed (breast cancer imaging) and Regeneration Matrix (nerve regeneration) before joining OBMedical in early 2016.

Mr. Samuels is a graduate of the Georgia Institute of Technology, where he earned a Bachelor of Science in Physics and a Master of Science. In addition, Mark holds numerous patents, has earned an Emmy for technical innovation and is a licensed pilot.

Neil Euliano, Ph.D.

Dr. Euliano has a Ph.D. in Signal Processing and Electrical Engineering from the University of Florida. In 2002 he initiated and led the program that created the technical foundation for LaborView. He is OBMedical’s co-founder and CTO and President and founder of Convergent Engineering; a biomedical research and development firm in Gainesville, Florida. Prior to founding Convergent Engineering Dr. Euliano was the Vice President of R & D for NeuroDimension, Inc., a neural network software company, and worked as a Systems Engineer at AT&T Bell Labs. He has spent the past 20 years leading medical device and technology development teams. Dr. Euliano was Convergent Engineering’s chief designer and manager of the FDA-cleared Philips VentAssist team that developed intelligent decision support software for ventilated patients. He has many refereed publications and holds over 30 US patents.

Regulatory Affairs

Paul E. Dryden, President of ProMedic, Inc., provides market assessments, regulatory approval strategies and process, 510(k), strategic partnerships and distributions, market research, clinical trial development, and other associated services to the medical device industry. He has been involved in preparation, submission and review of over 600 Premarket Notification 510(k)s since 1996.

Mr. Dryden is a graduate of Purdue University, where he earned his Bachelor of Science in Microbiology. In addition, he earned a Masters in Business Administration from Butler University.